This Treg subpopulation was enriched in the peripheral blood of CRC patients, which correlated with tumor progression, suggesting that CD4+Foxp3+LAP+ Tregs may have clinical application as markers of tumor-specific Tregs in CRC patients. This evidence concerns the gene CD4 and neoplasm.